1. Mullany K, Minneci M, Monjazeb R, Coiado OC. Overview of ectopic pregnancy diagnosis, management, and innovation. Women’s Health. 2023;19:17455057231160349.
Google Scholar
2. Schneider J, Berger CJ, Cattell C. Maternal mortality due to ectopic pregnancy. A review of 102 deaths. Obstet Gynecol. 1977;49(5):557–561.
Google Scholar
3. Centers for Disease Control and Prevention. Ectopic pregnancy mortality – Florida, 2009–2010. MMWR Morb Mortal Wkly Rep. 2012;61(6):106–109.
Google Scholar
4. Hirschler LE, Soti V. The Utility of Monitoring Beta-Human Chorionic Gonadotropin Levels in an Ectopic Pregnancy. Cureus. 2023;15(1):e34063.
Google Scholar
5. Refaat B, Bahathiq AO. The performances of serum activins and follistatin in the diagnosis of ectopic pregnancy: A prospective case-control study. Clin Chim Acta. 2020;500:69–74.
Google Scholar
6. Horne AW, Brown JK, Tong S, Kaitu’u-Lino T. Evaluation of ADAM-12 as a diagnostic biomarker of ectopic pregnancy in women with a pregnancy of unknown location. PloS One. 2012;7(8):e41442.
Google Scholar
7. Ghafouri-Fard S, Shoorei H, Taheri M. The role of microRNAs in ectopic pregnancy: A concise review. Non-coding RNA Res. 2020;5(2):67–70.
Google Scholar
8. Zou S, Li X, Feng Y, Sun S, Li J, et al. Comparison of the diagnostic values of circulating steroid hormones, VEGF-A, PIGF, and ADAM12 in women with ectopic pregnancy. J Transl Med. 2013;11:44.
Google Scholar
9. Ugurlu EN, Ozaksit G, Karaer A, Zulfikaroglu E, Atalay A, et al. The value of vascular endothelial growth factor, pregnancy-associated plasma protein- A, and progesterone for early differentiation of ectopic pregnancies, normal intrauterine pregnancies, and spontaneous miscarriages. Fertil Steril. 2009;91(5):1657–1661.
Google Scholar
10. Rajtar-Ciosek A, Wyroba J, Kacalska-Jansen O, Zmaczyński A, Figuła J, et al. Markers of implantation in ectopic and high-risk early eutopic pregnancies. Folia Med Cracov. 2016;56(3):41–50.
Google Scholar
11. Abuduxukuer R, Chen X, Ni J, Li S, Lu W. Day 4 and day 0 neutrophil-to-lymphocyte ratios as predictors of treatment failure with single-dose methotrexate for ectopic pregnancies. Int J Gynaecol Obstet. 2024;165(1):131–137.
Google Scholar
12. Yu Y, Li Y, Yang X, Fan Q, Cao D, et al. Daily variations and levels of human chorionic gonadotropin before methotrexate treatment as predictors of treatment success. J Obstet Gynaecol Res. 2022;48(12):3128–3136.
Google Scholar
13. Dereli ML, Savran Üçok B, Özkan S, Sucu S, Topkara S, et al. The importance of blood-count-derived inflammatory markers in predicting methotrexate success in patients with tubal ectopic pregnancy. Int J Gynaecol Obstet. 2024;167(2):789–796.
Google Scholar
14. Vadakekut ES, Gnugnoli DM. Ectopic Pregnancy. National Library of Medicine, StatPearls Publishing, Accessed July 11, 2025, https://www.ncbi.nlm.nih. gov/books/NBK539860/
Google Scholar
15. Bachman EA, Barnhart K. Medical management of ectopic pregnancy: a comparison of regimens. Clin Obstet Gynecol. 2012;55(2):440–447. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 94: Medical management of ectopic pregnancy. Obstet Gynecol. 2008;111(6):1479–1485.
Google Scholar
17. Beguin C, Brichant G, De Landsheere L, Tebache L, Karampelas S, et al. Use of methotrexate in the treatment of ectopic pregnancies: a retrospective single center study. Facts Views Vis Obgyn. 2019;11(4):329–335.
Google Scholar
18. Alsammani MA, Moona NA. Predictors of Success of a Single-Dose Methotrexate in the Treatment of Ectopic Pregnancy. J Obstet Gynaecol India. 2016;66(4):233–238.
Google Scholar
19. Zieba W, Guzowski G, Sieroszewski P. Ectopic pregnancy – a comparision of treatment methods in terms of effectiveness and impact on fertility. Ginekol Pol. 2025 Mar 19, https://doi.org/10.5603/gpl.101849.
Google Scholar
20. Wyroba J, Rajtar-Ciosek A, Kacalska-Janssen O, Babczyk D, Zmaczyński A, et al. Ocena skuteczności zachowawczego leczenia metotreksatem ciąż ektopowych w Klinice Endokrynologii Ginekologicznej Szpitala Uniwersyteckiego. Przegląd Lekarski. 2017;74(5):204–209. Accessed July 11, 2025, https://ruj.uj.edu.pl/server/api/core/bitstreams/b9a4b6d8-d5a5-46bd-a60a-ba8bdf-91d49d/content
Google Scholar
21. Vidal A, Geiger J, Vinayahalingam V, Pape J, Gulz M, et al. High live birth rates after laparoscopic isthmocele repair in infertility: a systematic review and meta-analysis. Front Endocrinol. 2025;16:1507482.
Google Scholar
22. Abdelazim IA, Shikanova S, Farag MH, Karimova B. Successful treatment of interstitial ectopic pregnancy using methotrexate. Ginekol Pol. 2023;94(11):944–945.
Google Scholar
23. Dunphy L, Haresnape C, Furara S. Interstitial ectopic pregnancy successfully treated with methotrexate. BMJ Case Rep. 2023;16(4):e252588.
Google Scholar
24. Tipiani-Rodríguez O, Elías-Estrada JC, Bocanegra-Becerra YL, Ponciano-Biaggi MA. ratamiento del embarazo ectópico implantado en cicatriz de cesárea: estudio de cohorte 2018-2022, Lima, Perú. Rev Colomb Obstet Ginecol. 2023;74(2):128–135.
Google Scholar
25. Mraihi F, Buzzaccarini G, D’Amato A, Laganà AS, Basly J, et al. Cornual Pregnancy: Results of a Single-Center Retrospective Experience and Systematic Review on Reproductive Outcomes. Medicina. 2024;60(1):186.
Google Scholar
26. Elson CJ, Salim R, Potdar N, Chetty M, Ross JA, et al. on behalf of the Royal College ofObstetricians and Gynaecologists. Diagnosis and Management of Ectopic Pregnancy. BJOG. 2016;123(13):e15–55.
Google Scholar
27. Solangon SA, Van Wely M, Van Mello N, Mol BW, Ross JA, et al. Methotrexate vs expectant management for treatment of tubal ectopic pregnancy: An individual participant data meta-analysis. Acta Obstet Gynecol Scand. 2023;102(9):1159–1175.
Google Scholar
28. Wang L, Cai C, Huang L, Shi D, Chen Q, et al. Safety profile of methotrexate used off-label in ectopic pregnancy: an active monitoring study based on a Chinese hospital pharmacovigilance system. Curr Med Res Opin. 2024;40(1): 35–42.
Google Scholar
29. Almutairy S, Aldakhil LO. Clinical Presentation as a Predictor of the Response to Methotrexate Therapy in Patients with Ectopic Pregnancy. J Pregnancy. 2022;2022:5778321.
Google Scholar
30. Helmy S, Sawyer E, Ofili-Yebovi D, Yazbek J, Ben Nagi J, et al. Fertility outcomes following expectant management of tubal ectopic pregnancy. Ultrasound Obstet Gynecol. 2007;30(7):988–993.
Google Scholar
31. Mol F, van Mello NM, Strandell A, Strandell K, Jurkovic D, et al. Salpingotomy versus salpingectomy in women with tubal pregnancy (ESEP study): an open-label, multicentre, randomised controlled trial. Lancet. 2014;383(9927):1483–1489.
Google Scholar
32. Lund Kårhus L, Egerup P, Wessel Skovlund C, Lidegaard Ø. Long-term reproductive outcomes in women whose first pregnancy is ectopic: a national controlled follow-up study. Hum Reprod. 2013;28(1):241–246.
Google Scholar
33. Jordan RL, Wilson JG, Schumacher HJ. Embryotoxicity of the folate antagonist methotrexate in rats and rabbits. Teratology. 1977;15(1):73–79.
Google Scholar
34. Hyoun SC, Običan SG, Scialli AR. Teratogen update: methotrexate. Birt Defects Res A Clin Mol Teratol. 2012;94(4):187–207.
Google Scholar
35. Cassina M, Clementi M. Aminopterin/methotrexate embryofetopathy. Orphanet. Accessed July 11, 2025, https://www.orpha.net/en/disease/detail/190836. Hanoodi M, Mittal M. Methotrexate. National Library of Medicine, StatPearls Publishing, Accessed July 11, 2025, https://www.ncbi.nlm.nih.gov/books/NBK556114
Google Scholar
37. Charache S, Condit Pt, Humphreys SR. Studies on the folic acid vitamins. IV. The persistence of amethopterin in mammalian tissues. Cancer. 1960;13(2):236–240.
Google Scholar
38. Sammaritano LR, Bermas BL, Chakravarty EE, Chambers C, Clowse MEB, et al. 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Care Res. 2020;72(4):461–488.
Google Scholar
39. Ostensen M, Hartmann H, Salvesen K. Low dose weekly methotrexate in early pregnancy. A case series and review of the literature. J Rheumatol. 2000;27(8):1872–1875.
Google Scholar
40. Kozlowski RD, Steinbrunner JV, MacKenzie AH, Clough JD, Wilke WS, et al. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am J Med. 1990;88(6):589–592.
Google Scholar
41. Lewden B, Vial T, Elefant E, Nelva A, Carlier P, et al. Low dose methotrexate in the first trimester of pregnancy: results of a French collaborative study. J Rheumatol. 2004;31(12):2360–2365.
Google Scholar
42. Martínez Lopez JA, Loza E, Carmona L. Systematic review on the safety of methotrexate in rheumatoid arthritis regarding the reproductive system (fertility, pregnancy, and breastfeeding). Clin Exp Rheumatol. 2009;27(4):678–684.
Google Scholar
43. Svirsky R, Rozovski U, Vaknin Z, Pansky M, Schneider D, et al. The safety of conception occurring shortly after methotrexate treatment of an ectopic pregnancy. Reprod Toxicol. 2009;27(1):85–87. Boots CE, Hill MJ, Feinberg EC, Lathi RB, Fowler SA, et al. Methotrexate does not affect ovarian reserve or subsequent assisted reproductive technology outcomes. J Assist Reprod Genet. 2016;33(5):647–656.
Google Scholar
45. Hill MJ, Cooper JC, Levy G, Alford C, Richter KS, et al. Ovarian reserve and subsequent assisted reproduction outcomes after methotrexate therapy for ectopic pregnancy or pregnancy of unknown location. Fertil Steril. 2014;101(2):413–419.
Google Scholar
46. Sahin Ersoy G, Turhan OT, Sakin O, Bulut S. Comparison of the long-term effects of single-dose methotrexate and salpingectomy on ovarian reserve in terms of anti-müllerian hormone levels. Hum Fertil. 2016;19(4):262–267.
Google Scholar
47. Zargar M, ShahAli S, Moramezi F, Shahbazian N. Effect of Single and Multiple Methotrexate Doses Treatment on Ovarian Reserve in Ectopic Pregnancy Women: A Prospective Cohort Study. J Obstet Gynaecol India. 2025;75(1): 22–27.
Google Scholar
48. Rezavand N, Yousefi P, Rezaei M, Hematti M, Kamravamanesh A, et al. A Comparative Analysis of Ovarian Reserve Rates Before and After Ectopic Pregnancy Treatment: A Cross-Sectional Analytical Study. J Kermanshah Univ Med Sci. 2025;29(1):e156619.
Google Scholar
49. Çetin F, Tepe NB, Kutlar AI. Evaluation of the effect of multi-dose methotrexate therapy on ovarian reserve in ectopic pregnancies: is polycystic ovarian morphology a protective condition for ovarian reserve?. Ginekol Pol. 2023;94(5):407–414.
Google Scholar
50. Sowter MC, Farquhar CM, Petrie KJ, Gudex G. A randomised trial comparing single dose systemic methotrexate and laparoscopic surgery for the treatment of unruptured tubal pregnancy. BJOG. 2001;108(2):192–203.
Google Scholar
51. Long Y, Lin Y, He J, Zhu R. Treatment outcomes of tubal pregnancy with tubal preservation: A meta-analysis. Medicine. 2023;102(47):e36165.
Google Scholar
52. Hajenius PJ, Engelsbel S, Mol BW, Van der Veen F, Ankum WM, et al. Randomised trial of systemic methotrexate versus laparoscopic salpingostomy in tubal pregnancy. Lancet. 1997;350(9080):774–779.
Google Scholar
53. Khani B, Ahmadi M, Rouholamin S. Comparison the Results of Hysterosalpangiography in Patients with Ectopic Pregnancy Treated by Laparoscopic Salpingostomy, Laparotomy, and Treated with Methotrexate. Adv Biomed Res. 2022;11:27.
Google Scholar
54. Melcer Y, Gat I, Dvash S, Copel L, Pekar-Zlotin M, et al. Tubal patency assessment using sequential transvaginal ultrasound and hysterosalpingo-foam sonography after methotrexate treatment for tubal pregnancy. Reprod Biomed Online. 2022;44(2):310–315.
Google Scholar
55. Hao H-J, Feng L, Dong L-F, Zhang W, Zhao X-L. Reproductive outcomes of ectopic pregnancy with conservative and surgical treatment: A systematic review and meta-analysis. Medicine. 2023;102(17):e33621.
Google Scholar
56. Wyroba J, Krzysiek J, Rajtar-Ciosek A, Kacalska-Janssen O, Zmaczyński A, et al. High live birth rate after conservative treatment of ectopic pregnancy with methotrexate. Ginekol Pol. 2014;85(2):105–110.
Google Scholar
57. Reis YA, Varli EN, Dereli ML, Aktas TD, Tolunay HE, Erkaya S. Short-term Reproductive Outcomes of Nulliparous Women with Previous Ectopic Pregnancy. J Coll Physicians Surg Pak. 2022;32(8):987–990.
Google Scholar
58. Khalil A, Saber A, Aljohani K, Khan M. The Efficacy and Success Rate of Methotrexate in the Management of Ectopic Pregnancy. Cureus. 2022;14(7):e26737.
Google Scholar
59. Mackenzie SC, Moakes CA, Duncan WC, Tong S, Horne AW. Subsequent pregnancy outcomes among women with tubal ectopic pregnancy treated with methotrexate. Reprod Fertil. 2023;4(2):e230019.
Google Scholar
60. Fıratlıgil FB, Sucu S, Sucu ST, Ozkan MA, Reis YA, et al. Comparison of 2-year reproductive outcomes of tubal ectopic pregnancies treated with surgery, methotrexate or expectant management. Arch Gynecol Obstet. 2024;310(5):2561–2568.
Google Scholar
61. Dur R, Nalcakan A, Aytekin O, Cirik DA, Yaniktepe B, et al. The effects of conservative and surgical approaches in tubal ectopic pregnancy on fertility. Ann Saudi Med. 2024;44(3):141–145.
Google Scholar
62. Alanwar A, Khalaf WM, Alfussaily E, Salem MA, Taema MI, et al. The impact of systemic methotrexate and surgical management on fertility preservation in tubal ectopic pregnancy among Saudi women. J Matern-Fetal Neonatal Med. 2023;36(2):2241106.
Google Scholar
63. Yeong CT, Wong PC. In vitro fertilization: indications, stimulation and clinical techniques. In: Kovacs G (ed.). The Subfertility Handbook A Clinician’s Guide. 2nd ed. Cambridge University Press:123–134.
Google Scholar
ENG
,
Kinga Michalewska
https://doi.org/10.48269/MandPH-AFMKU-24-2-001
